Publications by authors named "Emily Weng"

Claim this Profile
D
Duodenal Polyposis: An Incidental Finding of Duodenal-Type Follicular Lymphoma.
Rachael Hagen, Jasmine Tidwell, Emily Weng, Steven A Goldenberg, Anjiya Shaikh

Cureus· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EUS diagnosis of submucosal rectal squamous cell carcinoma.
Xiang Liu, Emily Weng, Murali Dharan

VideoGIE· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CELER: A 365-Participant Corpus of Eye Movements in L1 and L2 English Reading.
Yevgeni Berzak, Chie Nakamura, Amelia Smith, Emily Weng, Boris Katz

Open Mind (Camb)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J Moran, Emily Y Weng

Eur Respir J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraperitoneal and Extraperitoneal Colonic Perforation Following Diagnostic and Therapeutic Colonoscopy with Crohn's-related Stricture Dilation.
Emily Weng, Damian N Valencia, Zoltan A Krudy, Median Ali

Cureus· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
Linda Stein-Gold, Leon Kircik, Zoe Diana Draelos, Philip Werschler, Janet DuBois, Emily Weng

J Drugs Dermatol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Zoe Diana Draelos, Michael H Gold, Robert A Weiss, Leslie Baumann, Steven K Grekin, Emily Weng

J Am Acad Dermatol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Leslie Baumann, David J Goldberg, Linda Stein Gold, Emil A Tanghetti, Edward Lain, Emily Weng

J Drugs Dermatol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Leon H Kircik, Janet DuBois, Zoe Diana Draelos, Philip Werschler, Kimberly Grande, Emily Weng

J Drugs Dermatol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
Linda Stein-Gold, Leon H Kircik, Zoe Diane Draelos, Philip Werschler, Janet DuBois, Emily Weng

J Am Acad Dermatol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Dee Anna Glaser, David M Pariser, Adelaide A Hebert, Ian Landells, Chris Somogyi, Emily Weng

Pediatr Dermatol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.
Jean Carruthers, Kenneth Beer, Alastair Carruthers, William P Coleman, Zoe Diana Draelos, Emily Weng

Dermatol Surg· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials.
David Wirta, David M Pariser, Steven G Yoelin, Seiji Arase, Amy McMichael, Emily Weng

J Clin Aesthet Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resveratrol and para-coumarate serve as ring precursors for coenzyme Q biosynthesis.
Letian X Xie, Kevin J Williams, Cuiwen H He, Emily Weng, San Khong

J Lipid Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects.
David Wirta, Leslie Baumann, Suzanne Bruce, Gurpreet Ahluwalia, Emily Weng

J Clin Aesthet Dermatol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
Steven Fagien, John G Walt, Jean Carruthers, Sue Ellen Cox, David Wirta, Emily Weng

Aesthet Surg J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed accumulation of intestinal coliform bacteria enhances life span and stress resistance in Caenorhabditis elegans fed respiratory deficient E. coli.
Fernando Gomez, Gabriela C Monsalve, Vincent Tse, Ryoichi Saiki, Emily Weng

BMC Microbiol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
Stacy Smith, Steven Fagien, Scott M Whitcup, Fred Ledon, Christine Somogyi, Emily Weng

J Am Acad Dermatol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.
David Wirta, Amanda M Vandenburgh, Emily Weng, Scott M Whitcup, Sef Kurstjens

Clin Ophthalmol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis